Menu
Advancing the Next Generation of Periodontitis Therapies.
Underpinned by cutting-edge scientific research conducted by established experts.
Periodontitis is a persistent inflammatory disease that affects the gums and the supporting structures of teeth. While generic antibiotics have traditionally been a standard treatment for periodontitis, the emergence of antibiotic resistance poses a significant challenge to their long-term efficacy.
OROCIDIN’s mission is to develop the preferred treatment against aggressive periodontitis. Our innovative therapeutic agent, QR-01, distinguishes itself through its unique ability to provide treatment without exacerbating the pressing concern of antibiotic resistance.
Business Model
Establish strategic partnership with a well-established drug delivery company that possesses strong proprietary technology.
Drug formulation development and pre-clinical tests.
Generate new intellectual property (IP) rights.
Commence the initial clinical Proof of Concept (POC)study.
The anticipated timeline for advancing the development project for periodontitis and establish the global IP rights is approx. 30 months, starting in October 2023.
QR-01 is an antimicrobial peptides (AMPs), also called host defence peptides (HDPs) are part of the innate immune response found among all classes of life. These peptides are potent, broad spectrum antimicrobials, which demonstrate potential as novel therapeutic agents. Unlike the majority of conventional antibiotics it appears that antimicrobial peptides frequently destabilize biological membranes, can form transmembrane channels, and may also have the ability to functioning as immunomodulators.
Connect with us, and stay updated.
Receive our latest blog posts directly in your inbox!